Table of Contents List of Tables List of Figures Introduction Global Markets Direct Report Coverage Nocturia - Overview Nocturia - Therapeutics Development Pipeline Overview Pipeline by Companies Products under Development by Companies Nocturia - Therapeutics Assessment Assessment by Target Assessment by Mechanism of Action Assessment by Route of Administration Assessment by Molecule Type Nocturia - Companies Involved in Therapeutics Development Astellas Pharma Inc Ferring International Center SA Sanwa Kagaku Kenkyusho Co Ltd Vantia Therapeutics Nocturia - Drug Profiles (acetaminophen + ibuprofen) - Drug Profile Product Description Mechanism Of Action R&D Progress ASP-7035 - Drug Profile Product Description Mechanism Of Action R&D Progress ASP-7398 - Drug Profile Product Description Mechanism Of Action R&D Progress desmopressin acetate ODT - Drug Profile Product Description Mechanism Of Action R&D Progress FE-201836 - Drug Profile Product Description Mechanism Of Action R&D Progress fedovapagon - Drug Profile Product Description Mechanism Of Action R&D Progress SK-1404 - Drug Profile Product Description Mechanism Of Action R&D Progress Nocturia - Dormant Projects Nocturia - Product Development Milestones Featured News & Press Releases Aug 08, 2017: Ferring Pharmaceuticals: The Scottish Medicines Consortium Approves Use of NOQDIRNA (oral lyophilisate desmopressin), the First Licensed Treatment for Nocturia due to Idiopathic Nocturnal Polyuria in Adults Aug 07, 2017: Noqdirna is accepted for restricted use within NHS Scotland Feb 13, 2017: Scottish Medicines Consortium Rejects Noqdirna For Use Within NHS Scotland Appendix Methodology Coverage Secondary Research Primary Research Expert Panel Validation Contact Us Disclaimer

List of Tables Number of Products under Development for Nocturia, H1 2018 Number of Products under Development by Companies, H1 2018 Products under Development by Companies, H1 2018 Number of Products by Stage and Target, H1 2018 Number of Products by Stage and Mechanism of Action, H1 2018 Number of Products by Stage and Route of Administration, H1 2018 Number of Products by Stage and Molecule Type, H1 2018 Nocturia - Pipeline by Astellas Pharma Inc, H1 2018 Nocturia - Pipeline by Ferring International Center SA, H1 2018 Nocturia - Pipeline by Sanwa Kagaku Kenkyusho Co Ltd, H1 2018 Nocturia - Pipeline by Vantia Therapeutics, H1 2018 Nocturia - Dormant Projects, H1 2018 List of Figures Number of Products under Development for Nocturia, H1 2018 Number of Products under Development by Companies, H1 2018 Number of Products by Targets, H1 2018 Number of Products by Stage and Targets, H1 2018 Number of Products by Mechanism of Actions, H1 2018 Number of Products by Stage and Mechanism of Actions, H1 2018 Number of Products by Routes of Administration, H1 2018 Number of Products by Stage and Routes of Administration, H1 2018 Number of Products by Molecule Types, H1 2018 Number of Products by Stage and Molecule Types, H1 2018

Astellas Pharma Inc Ferring International Center SA Sanwa Kagaku Kenkyusho Co Ltd Vantia Therapeutics